ArticleInternational journal of obesity (2005)2026
The impact of adjuvant anti-obesity medications on 10-year weight loss outcomes after sleeve gastrectomy.
Article in International journal of obesity (2005), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFew studies have documented 10-year outcomes after sleeve gastrectomy (SG) in patients in the United States (US). This single-institution retrospective study reviewed longitudinal weight loss in young patients who underwent SG more than 10 years ago and followed their adjuvant use of semaglutide and tirzepatide. We hypothesized that adjuvant AOM use would be associated with better long-term weight outcomes.
methodsWe retrospectively reviewed records of all adult patients at our institution who underwent SG before 45 years old between January 2013 and December 2014. Patients were required to have BMI data available at least 9.5 years after SG, and those who underwent conversion to gastric bypass (RYGB) were excluded. Longitudinal weight loss outcomes were compared between patients taking semaglutide and/or tirzepatide for at least 1 year at the most recent documented visit and patients not taking adjuvant AOMs at the most recent visit.
results111 patients met the criteria for inclusion. There were 67 patients not taking adjuvant AOMs and 44 patients taking adjuvant AOMs at the most recent visit (semaglutide in 29 patients and tirzepatide in 15 patients). In patients not taking adjuvant AOMs, the mean percent total weight loss (%TWL) was 14.1% at mean 10.6 years after SG. In patients taking adjuvant AOMs, mean %TWL was 25.7% at mean 10.7 years after SG (p < 0.001). On average, patients started AOMs 7.6 years after SG and had been taking AOMs for 3.0 years at the time of most recent visit. Groups had similar weight loss trajectories prior to initiation of adjuvant medications.
conclusionAmong younger patients who underwent SG at our institution more than 10 years ago, patients currently taking adjuvant semaglutide and/or tirzepatide demonstrated significantly better long-term weight loss than patients not taking adjuvant AOMs. This study suggests that adjuvant AOMs can optimize long-term weight outcomes after SG, even when started many years postoperatively.
Indexed as
Identifiers
42225949What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.